Partnership to Develop Protein Formulation for Cartilage Repair

Nanomedicine R&D company Carlina Technologies (Angers, France), has signed an agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair.  Financial details were not disclosed. 

The product development process uses the PEPTIDOT^TM technology platform for encapsulation of therapeutic peptides and proteins without altering their structure, therefore maintaining their full biological activity. Initially targeting off-patent drugs, Carlina currently offers improved treatments for diabetes, growth hormone deficiencies and a tumour-targeted anticancer nanomedicine to treat companion animals with cancer. It also provides R&D services in formulation development with out-licensing opportunities to improve the efficacy and safety of proprietary drugs from the pharma & veterinary industries.

This agreement provides an option for Laboratoires Genévrier spin-off GenBiotech, to acquire worldwide rights on the PEPTIDOT platform to develop, sub-license, or commercialise this product specifically for cartilage repair for animal health.

“Nanomedicines and their development programs are becoming critical to the pharmaceutical industry. Carlina Technologies has been working with GenBiotech for a number of years and we are delighted that our collaboration will be expanded with a partnership agreement,” said Olivier Meyer, President & CEO of Carlina Technologies. “This collaboration will contribute to the development of an important protein in the much needed bone cartilage repair area.”